$792 Million is the total value of EcoR1 Capital, LLC's 41 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 157.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XNCR | Buy | XENCOR ORD | $84,378,000 | -11.8% | 2,501,557 | +7.1% | 10.66% | +10.3% |
| PRTA | Buy | PROTHENA ORD | $73,905,000 | +866.7% | 9,426,640 | +1203.3% | 9.33% | +1107.4% |
| ONCE | Buy | SPARK THERAPEUTICS ORD | $69,320,000 | +10.3% | 714,789 | +16.4% | 8.75% | +37.8% |
| DRNA | Buy | DICERNA PHARMACEUTICALS ORD | $56,908,000 | +9.0% | 3,962,978 | +19.5% | 7.19% | +36.2% |
| SLDB | Buy | SOLID BIOSCIENCES ORD | $34,563,000 | +626.9% | 3,342,691 | +304.2% | 4.36% | +809.4% |
| FGEN | Buy | FIBROGEN ORDcall | $24,130,000 | +92.5% | 652,500 | +135.1% | 3.05% | +140.5% |
| HARP | Buy | HARPOON THERAPEUTICS ORD | $19,990,000 | +14.0% | 1,463,423 | +8.5% | 2.52% | +42.5% |
| SRPT | New | SAREPTA THERAPEUTICS ORD | $14,292,000 | – | 189,745 | +100.0% | 1.80% | – |
| XCUR | New | EXICURE ORD | $13,954,000 | – | 5,515,225 | +100.0% | 1.76% | – |
| GOSS | New | GOSSAMER BIO INC ORDcall | $13,432,000 | – | 800,000 | +100.0% | 1.70% | – |
| NXTC | New | NEXTCURE ORD | $7,728,000 | – | 250,500 | +100.0% | 0.98% | – |
| NLTX | New | NEOLEUKIN THERAPEUTICS ORD | $6,458,000 | – | 2,265,880 | +100.0% | 0.82% | – |
| MRUS | New | MERUS ORD | $2,951,000 | – | 165,600 | +100.0% | 0.37% | – |
| IGMS | New | IGM BIOSCIENCES ORD | $1,775,000 | – | 100,000 | +100.0% | 0.22% | – |
| ZFGN | New | ZAFGEN ORD | $1,437,000 | – | 1,944,500 | +100.0% | 0.18% | – |
| CRTX | New | CORTEXYME ORD | $1,246,000 | – | 49,993 | +100.0% | 0.16% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES ORD | $950,000 | – | 96,600 | +100.0% | 0.12% | – |
| AUTL | New | AUTOLUS THERAPEUTICS ADRsponsored adr | $859,000 | – | 69,155 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.